Experts challenge FDA over approval for new dose of Alzheimer's drug
Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts in the British Medical Journal today.
Mar 22, 2012
0
0